(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
Oramed Pharmaceuticals (ORMP) is a technology pioneer in delivering insulin orally to diabetes patients, which is currently delivered via injection. Other drug makers haven't succeeded yet in developing insulin in the pill form.
Oramed has huge potential in developing diabetes drugs in oral form and its stock has significant upside potential too. Oramed is currently trading around $6.80 with a market cap of approximately $50 million. It's a micro-cap company, and investors should note that there are risks inherent in micro-cap investing.
Oramed is seeking to revolutionize the treatment of diabetes mellitus through its proprietary flagship product,...
Only subscribers can access this article, which is part of the PRO research library covering 3,603 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: